The announcement of a mixed shelf offering typically leads to concerns about dilution of existing shares, which can negatively impact the stock price in the short term. Given that Legend Biotech has made such an announcement, it is reasonable to expect a negative impact on its stock price as investors react to the potential increase in supply of the company's securities.